Arkolith/Insider Trading/ALLO/Form 4

Chang David D

President and CEO, DirectorAllogene Therapeutics, Inc. (ALLO) · full profile →Form 4 · filed Jan 31, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 25, 2024Grant(A)318K—$04.5M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 25, 2024Grant(A)1.1M—$01.1M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001593968-24-000192) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML